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Introduction
Autoimmune epithelitis [1], designated Sjögren’s syn-
drome (SS), primarily aﬀ  ects the lacrimal and salivary 
glands (SGs), the destruction of which results in xero-
phthalmia and xerostomia. Regardless of whether this 
condition presents alone as primary SS or associated with 
other connective tissue diseases as secondary SS [2], the 
epithelial structures of the secretory organs are wrapped 
in a sheath of lymphocytes. Th   ese aggregates are 
predominated by T lymphocytes, most of which are 
CD4+ rather than the CD8+ T lineage [3]. We [4] and 
others [5-7] have also described germinal center (GC)-
like structures of B cells (Figure 1) inﬁ  ltrating exocrine 
tissues.
Several contradictory hypotheses have been forwarded 
to resolve the complexity of the syndrome [8]. Th  e  con-
tinuing progress in discovering lymphocyte subsets and 
the lengthening list of cytokines involved, together with 
how they are aﬀ  ected in SS, has further fuelled the debate 
on SS pathogenesis. Th  is has been extended to include 
whether excessive production of cytokines might contri-
bute to clinical symptoms of SS, such as fever, arthralgia 
and long-term asthenia.
CD4+ T helper (Th  ) lymphocytes have long been 
known to be distributed into Th   1 and Th   2 cells, based on 
distinct cytokine patterns [9]. Imbalances between type-1 
cytokine-producing Th   1 cells and type-2 cytokine-
producing Th   2 cells have been considered as predisposing 
to autoimmunity. At the time of their seminal discovery, 
however, Mosmann and Coﬀ   man [10] predicted that 
more Th   -cell subsets exist, and indeed numerous Th    cell 
lineages have since been identiﬁ  ed. In particular, Th  17 
cells were described and IL-17 acknowledged as a prime 
representative of the new generation of proinﬂ  ammatory 
cytokines [11]. Concomitantly, regulatory T (Treg) cells 
were identiﬁ  ed as a unique population of Th   cells that 
restrain excessive activation of eﬀ  ector lymphocytes [12] 
and maintain T- and B-cell tolerance to self antigens.
Despite much progress, controversy over which set(s) 
of lymphocytes and group(s) of cytokines initiate SS 
pathogenesis persists. In the past, T cells have been 
claimed to be capable of initiating autoimmunity on their 
own, with B cells conﬁ   ned to antibody production. 
Nevertheless, the failure of T-cell-directed therapies in 
treating such patients has raised doubts about a dominant 
role for T lymphocytes in SS. Th  is observation, made 
against increased recognition of the role of B lympho-
cytes in diseases and the eﬃ   cacy  of  B-cell-depleting 
agents [13], sparked interest in whether B cells play some 
role in the pathogenesis of SS [14]. Despite the dogma 
that they are instructed by T cells, compelling evidence 
has emerged for autonomous roles for B cells, including 
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© 2011 BioMed Central Ltdthe production of cytokines [15]. Accordingly, our 
current interpretation of cytokine-secreting B-cell sub-
sets stems from the Th    cell paradigm. Regulatory B (Breg) 
cells, recently described in humans [16], do exert 
regulatory eﬀ  ects through the production of cytokines. 
Furthermore, B-cell activation of the TNF family (for 
example, by B-cell-activating factor (BAFF), also known 
as B-lymphocyte stimulator (BLyS), and a proliferation-
inducing ligand (APRIL)) has further substantiated the 
concept of a notable role for B-cell cytokines in the 
pathogenesis of SS [17].
Th  e impact of abnormal cytokine production in this 
disease has attracted considerable attention [18]. Whilst 
the eﬀ  ect of a cytokine on one lymphocyte subset in SS 
can be discerned, it has become a challenge to understand 
how the interaction between several interconnected 
networks of cytokines impact on so many diﬀ  erent cell 
populations. Th   e concept that the interplay of cytokine-
producing T and B cells shifts the balance towards 
autoreactive T and B lymphocytes has been questioned. 
Recent ﬁ  ndings on the pathogenesis of SS are beneﬁ  cial 
at a time when cytokine-directed therapies are being 
tested for the treatment of inﬂ  ammatory  diseases. 
However, it remains highly complex to ascribe diﬀ  erent 
symptoms to just a single cytokine.
T-cell cytokines
The polarized Th cell paradigm
Upon T-cell activation, the cytokine milieu dictates Th   
cell polarization. Th   us, IFN-γ and IL-12 engage the T box 
transcription factor, referred to as Tbet, and the signal 
transducer and activator of transcription (Stat)-4, to 
transform naïve CD4+ T cells into Th   1 lymphocytes. Th  e 
latter cells are involved in the response to intracellular 
pathogens, thus inducing the production of IFN-γ and 
TNF-α, but not IL-4 and IL-13. In contrast, IL-2 and IL-7 
cause the binding of a speciﬁ  c transcription factor to the 
WGATAR nucleotide consensus sequence (GATA-3). 
Th  is promotion polarizes naïve T cells towards Th  2 
lymphocytes. Th  e latter cells are committed to the 
elimination of extracellular pathogens, thus favoring the 
production of IL-4 and IL-13. Undoubtedly, GATA-3 
represents the master transcription factor for Th  2 
diﬀ  erentiation. Although the two groups of cytokines are 
mutually inhibitory, IFN-γ opposes inﬂ  ammation  in 
certain disease settings, and IL-4 enhances IL-12 produc-
tion by macrophages, which in turn favors Th  1 polari-
zation of naïve Th   lymphocytes. Whereas uncon  trolled 
Th  1 cells determine autoimmune states, imbalances in 
Th  2 cells lead to allergic disorders. However, were this 
binary paradigm to be as presumed, no autoimmune 
traits should emerge in a proportion of patients with 
excessive Th   2 cells [19].
Patients with SS have long been thought to suﬀ  er from 
a Th   1-mediated condition. Such interpretation was 
supported by high levels of IFN-γ in serum [20] and a 
predominance of Th  1 over Th  2 cells in blood [21]. In 
addition, T cells containing mRNA for IFN-γ [22] and 
Stat-1 have been found in the SGs of patients with SS 
[23]. In fact, the contribution of each Th    subset to SS and 
their interconnections are more subtle than suggested by 
the earliest data. In this context, for Th   1 cells to underpin 
SS pathogenesis, one must verify that the activity of Th  1 
cells is decreased in the blood of patients, while increased 
in their SGs [24]. Furthermore, the cytokine pattern may 
shift from Th   1 to Th   2 as the immunopathological lesions 
progress, as postulated by Moutsopoulos’ group [25]. 
Supporting their hypothesis, they made the valuable 
observation that IFN-γ expression is associated with a 
high-grade inﬁ   ltrate of the SGs, whereas a low-grade 
inﬁ  ltrate is instead accompanied by a type-2 response.
The expanding universe of Th cell subsets
Th17 cells
Inevitably, the role of Th  1 and Th  2 cells in SS, gleaned 
from studies of cultured cells and from observations of 
SS patients, have become contradictory. Th  ese  discrepan-
cies were resolved by the discovery of IL-23, after which 
it was determined that abnormalities ﬁ  rst ascribed to Th  1 
cells were instead engendered by Th   17 cells, named after 
their IL-17 cytokine signature [11,26-29]. Th  17 cells 
produce a family of cytokines from IL-17A through IL-
17F, and, to a lesser extent, TNF-α and IL-22 [11]. 
Although IL-17 and IL-22 are structurally similar, they 
bind to distinct receptors and take part in separate 
intracellular pathways. Furthermore, in contrast to IL-17, 
IL-22 exerts minor proinﬂ  ammatory eﬀ  ects, and, under 
certain circum  stances, even protects from autoimmune 
Figure 1. Pathological changes in the salivary glands of 
patients with primary Sjögren’s syndrome. Left: toluidine blue 
staining unveils infi  ltrates of mononuclear cells corresponding to 
T lymphocytes (×16). Right: B cells forming an ectopic germinal 
center (×10).
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6 with either IL-1 or IL-21 via the orphan retinoid 
nuclear receptor γt, but neither Tbet nor GATA-3. IL-21, 
a member of the IL-2 family, collaborates with dendritic 
cell (DC)-derived transforming growth factor (TGF)-β to 
amplify the tendency to Th  17 cell diﬀ  erentiation  and 
induce these lymphocytes to express receptors for IL-23. 
Th  e latter cytokine is required for the maintenance of 
Th   17 [30,31]. It is interesting that, at least in mice, Th  17 
lymphocytes can also function as B-cell helpers [32]. 
Th  ey induce a pronounced antibody response, with 
preferential immunoglobulin (Ig) class switch to IgG2a 
and IgG3 for IL-17, and to IgG1 and IgG2b for IL-21. 
Th   ese results establish that Th   17 cells are crucial in GC 
formation.
In line with the mouse data, high serum [33] and saliva 
[34] levels of IL-17 have been reported in SS patients. In 
addition, their SGs exhibit a predominance of IL-17-
containing cells within the inﬂ   ammatory lesions [27], 
consistent with the production of IL-17 by ductal 
epithelial cells. Further work on SGs detected TGF-β, 
IL-6 and IL-23, all requisite promoters of Th  17  diﬀ  er  en-
tiation [31]. Th  ese  ﬁ  ndings add credence to the view that 
Th   17 cells are possible drivers of the persistent inﬂ  am  ma-
tory response in the SGs of patients with primary SS.
Regulatory T cells
An exciting aspect of homeostasis of the Th  17 cells is 
their reciprocal relationship with Treg cells. However, 
there is as yet no universal consensus on their deﬁ  nition. 
Th   ey were originally identiﬁ  ed by high membrane levels 
of CD25. Subsequent studies indicated that this pre-
requisite for identifying Treg cells did not ﬁ  t the obser-
vation that CD25-CD4+ T cells exert as many regulatory 
functions as CD25+CD4+ T cells. Th  e Treg cells were 
subsequently identiﬁ  ed by the abundance of the forkhead 
box protein P3 (Foxp3) transcriptional regulator. Foxp3+ 
cells develop in the thymus as natural Treg cells, or 
diﬀ  erentiate from naïve T lymphocytes in the presence of 
TGF-β as immune Treg cells. Natural Treg cells expres-
sing the inducible co-stimulate use IL-10 to suppress DC 
functions, and TGF-β to restrain T cells. Treg cells that 
do not express this inducible co-stimulate require TGF-β 
only [34].
Th  e reports are contradictory in that the blood of SS 
patients contains too many [35] or too few Treg cells [36]. 
Th   e real setting could be that Foxp3+ lymphocytes circu-
lating in the blood correlate inversely with those inﬁ  ltrat-
ing the SGs [37]. Th   e fact that there are fewer Treg cells 
in advanced than in mild SG inﬁ  ltrates supports the view 
that DC-derived TGF-β induces Foxp3 in naïve T cells 
and switches T-cell diﬀ   erentiation from the defective 
Treg cell pathway to a Th  17  diﬀ  erentiation pathway in the 
presence of IL-6 [30,31].
Similarly, IL-18, which can be secreted by epithelial 
cells, has been detected in periductal mononuclear cells 
(MNCs), and correlated with inﬁ  ltrating  macrophages 
and increases in serum IL-18 [26]. Th  is supplemental 
mediator would regulate the Th  1 response and amplify 
IL-17 synthesis [27]. At the time of its identiﬁ  cation, the 
pathological role of IL-18 in the SGs of SS patients was 
unclear. Since then, we have learned that IL-18 acts as a 
chemoattractant for CD4+ T cells and a stimulator for 
antigen-presenting cells, required for the generation of 
Th  17 cells (Figure 2). Furthermore, IL-18 promotes the 
synthesis of proinﬂ   ammatory cytokines, enhances the 
secretion of chemokines and worsens tissue damage 
through cell-mediated cytotoxicity and release of matrix 
metalloproteinases [28]. Ultimately, a handful of macro-
phages and DCs can play an IL-18-mediated active role 
in the SGs and in MNC inﬁ  ltration.
The role of IL-6 in Sjögren’s syndrome
Up-regulation of IL-6
Not only does IL-6 participate in the generation of Th  17 
cells but it also fosters their proliferation and is associated 
with multiple eﬀ  ects in patients with SS, whose SGs have 
been shown to contain IL-6. Given that it is also derived 
from Th   17 cells [38], IL-6 can activate local B cells in an 
autocrine manner. Th   e 80-kDa glycoprotein (gp) receptor 
for IL-6 associates with a signal-transducing 130-kDa gp 
chain to shape a membrane-bound aggregate. Th  e 
receptor for IL-6 also exists in a soluble form capable of 
binding to transmembrane gp130 and facilitating signal 
transduction through homodimerization of gp130 to the 
ligand-receptor complex [39]. Th  us, IL-6 exerts seem-
ingly opposite eﬀ  ects by lending strength to Th  17 cells 
and exerting polyclonal activation of B cells.
IL-6-related T- and B-cell biology
In the presence of IL-6, Th  17 cells orchestrate the 
development of GCs dominated by autoreactive lympho-
cytes [40], such as those that we have described in the 
SGs of SS patients [41]. Moreover, IL-6 contributes to the 
expression of recombination-activating genes (Rags). 
Even though some of the activities of IL-6 proceed via its 
soluble form, the predominance of complexes of IL-6 and 
the IL-6 receptor is the therapeutic rationale for targeting 
the receptor rather than the cytokine. Th   e soluble form 
may retain IL-6 and the complex bound to gp130 on the 
cell membrane and, thus, engage the receptor to the 
membrane again.
Th  is pivotal cytokine seems to be responsible for 
abnormal B-cell antigen receptor (BCR)-mediated regu-
la  tion of Rag genes in B cells in SS patients. Our own data 
[42] indicate that, along with BCR engagement, IL-6 
signaling results in secondary Ig gene rearrangements, 
and thereby favors the generation of auto-antibodies. Of 
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generation of Treg lymphocytes, and the ultimate 
suppressive eﬀ   ect of the latter cells on B lymphocyte 
responses.
Dysregulated production of IL-6 by B cells
As described in patients with rheumatoid arthritis and 
systemic lupus erythematosus, their spontaneous activa-
tion can induce B lymphocytes to release copious 
amounts of IL-6 in primary SS [43]. Furthermore, the 
IL-6 receptor is preferentially expressed on B cells in 
patients with active disease, and thereby preferentially 
stimulates the diﬀ   erentiation of autoreactive B 
lymphocytes.
B-cell cytokines
Polarized B lymphocytes
B cells possess the capacity to produce a range of cyto-
kines. Th   ese may be grouped as proinﬂ  ammatory 
cytokines, such as IL-1, IL-6, TNF-α and lymphotoxin 
(LT)-α; as immunosuppressive cytokines, such as TGF-β 
and IL-10; or as hematopoietic growth factors, such as 
IL-7 and granulocyte/macrophage-colony stimulating 
factor. Th  e third family facilitates Th  1 cell polarization 
and the production of TNF-α by DCs, and derives from 
macrophages and endothelial cells in the SGs of patients 
with SS [44].
In reality, the major breakthrough in determining the 
potential role of B cells in diseases occurred when two 
distinct cytokine-secreting subsets were identiﬁ  ed 
through the culture of B cells with eﬀ  ector  T  cells 
associated with their cognate antigens [15]. B lympho-
cytes polarized in the presence of Th  1 cells were desig-
nated B eﬀ   ector (Be)1 cells, based on their signature 
cytokines, IFN-γ and IL-2, in the expected presence of 
Tbet. Conversely, Th   2 cells induced naïve B lymphocyte 
polarization into Be2 cells, which produced IL-4 and 
IL-6, in the unexpected absence of GATA-3. However, 
IL-10, LT-β, TGF-β, and TNF-α were similarly expressed 
in Be1 and Be2 cells, yielding an ever-growing complexity 
of these B-cell subsets.
Th  e kinetics of Be cell generation and the cytokine 
proﬁ   le of B cells raise the possibility that the Th  1 
phenotype is imprinted on Be1 cells through IL-2 and 
that expression of IFN-γ by B cells is sustained through 
an autocrine loop between IFN-γ and the IFN-γ receptor. 
However, the diﬀ  erentiation of naïve B lymphocytes into 
IL-4-producing Be2 cells is controlled by T-cell-
dependent signals. Of important note, IL-4 is generated 
by GC B cells and is necessary for Th   2 polarization [45].
Interconnections between the B- and T-cell cytokine 
networks
LTs are implicated in establishing and maintaining the 
organization of normal lymphoid tissues. Mice in which 
LT-α [46] and/or LT-β [47] signaling is disrupted suﬀ  er 
from disturbances in splenic architecture. Intriguing also 
is the ﬁ  nding that DC networks, conspicuous compo-
nents of B-cell follicles, are lacking in diﬀ  erent LT knock-
out mice [48]. Gonzalez and colleagues [49] showed that 
Figure 2. The network of T helper (Th) cells gathers together Th0, Th1, Th2 and Th17 lymphocytes. The production of IFN-γ, transforming 
growth factor (TGF)-β and various interleukins is indicated. MØ, macrophage.
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transfer of B cells (but not T cells) from membrane LT-α-
positive mice (but not membrane LT-α-negative mice) 
governed the emergence of soluble LT-α in the SGs of 
IL-14α transgenic mice, a model of primary SS [50]. Th  us, 
signaling through LT-α was necessary to reduce aspects 
of SS in the SGs of non-obese diabetic mice [51].
Activated Th   cells crosstalk with activated B cells to 
regulate their respective responses. Conversely, Be cells 
modulate T-cell polarization. Th  e factors that aﬀ  ect 
T-cell diﬀ   erentiation toward Th  1 cells induce naïve B 
cells to produce IFN-γ via activation of Stat-3, the phos-
phorylation of which is initiated by IL-12 [52]. A high 
level of expression of IL-12 has been found in the SGs of 
SS patients [53], and IL-12-induced SG dysfunction in 
IL-12 transgenic mice oﬀ  ers a new model for primary SS 
[54]. MNCs inﬁ  ltrate their exocrine tissues, suggesting 
that IL-12 contributed to the circuit involving auto-
reactive T and B cells in SS. Interestingly, IL-10 produced 
by B cells suppresses IL-12 production by DCs, thus 
blocking Th   1 cell responses.
Once B cells have been induced to produce IFN-γ, the 
presence of Th   1 is no longer required to maintain polar-
ized Be cells. Th   is is because antigen-speciﬁ  c B lympho-
cytes take up antigen for presentation to T cells and, by 
doing so, create a self-sustaining circuit of B and T cells 
through which other naïve T cells may be recruited.
Aside from promoting Th   1 cell polarization, Be1 cells 
amplify IFN-γ production by T cells via a TNF-α-
mediated mechanism. Polarization of B cells may take 
place at sites of inﬂ  ammation, such as aﬀ  ected SGs [55]. 
Although patients with ectopic GCs have lower levels of 
Be2 cytokines than other SS patients, accumulating 
evidence supports the view that most of these B-cell 
clusters do not fulﬁ  ll the requisites for ectopic GCs, but 
constitute aggregates of immature B cells [36]. However, 
the high aﬃ     nity and class switch of auto-antibodies 
produced imply a local break of B-cell tolerance.
As suggested above, the proinﬂ  ammatory  IL-17, 
normally considered a T-cell-associated factor, has also 
been reported to be a central driver of GC-derived auto-
antibodies. Th  is was demonstrated by blocking IL-17 
signaling that disrupted the CD4+  T-cell and B-cell 
interactions required for the formation of GCs [40].
Additionally, memory B cells are markedly reduced in 
the circulation, possibly due to retention in inﬂ  amed SGs 
[56]. Th   eir ensuing accumulation, along with shedding of 
surface CD27 [57], and altered recirculation of B-cell 
subsets from these sites may all participate in the 
disturbed B-cell homeostasis in primary SS [58]. Given 
that CD27+ memory B cells present with a higher 
transmigratory capacity to CXCL12, also termed stromal 
cell-derived factor-1 (SDF-1), and to CXCL13, also 
termed B-cell-attracting chemokine-1 (BCA-1), than 
CD27- naïve B cells [59], glandular coexpression of these 
two chemokines [6,7,60] directs memory B cells prefer-
en  tially into inﬂ  amed SGs, where they reside [61].
Regulatory circuits
The transcription factor Tbet in T and B lymphocytes
Th  e  ﬁ  nding of Tbet in B cells had, in fact, been preceded 
by its description in T cells. Not only does the binding of 
IFN-γ to its receptor on the surface of naïve T cells 
activate and hence translocate Stat-1 into the nucleus, 
but this interaction also promotes the expression of 
transcription factors involved in Th   1 development. Th  us, 
Tbet induces the transcription of the IFN-γ gene, as well 
as the expression of receptors for IL-12. Th   e net result is 
that T cells become responsive to IL-12, and translocate 
Stat-1 into the nucleus, where IFN-γ expression is induced. 
In turn, IFN-γ drives T cells along the Th  1 pathway 
through a positive feedback loop.
Similarly, naïve B cells are equipped with receptors for 
IFN-γ, and can be induced to release Tbet-triggered 
IFN-γ in the presence of IL-12. Th   en, B-cell-derived IFN-
γ activates B cells in an autocrine manner, and ampliﬁ  es 
Th   1 responses through a paracrine pathway [55]. 
Consistent with this view is that Tbet-deﬁ  cient murine B 
cells skew antibody isotypes toward IgG1 and IgE, which 
are isotypes favored by Be2 cells.
GATA-3 and T-cell diff  erentiation
Th   e absence of GATA-3 in Be cells raises the question of 
whether it can be replaced by other transcription factors. 
By counteracting Tbet in T cells, GATA-3 regulates Th   
polarization directly and Be cell generation indirectly 
[62]. Th  is transcription factor diverts T-cell diﬀ  eren-
tiation towards Th  2 cells by silencing Th  1-cell-speciﬁ  c 
transcription factor, and thereby enabling Th  2 cells to 
proliferate. Co-culture of naïve B cells with Th  2 cells 
inhibits Tbet, reduces IFN-γ production and reverses the 
up-regulation of receptors for IL-12. Conversely, up-
regulation of IL-4 in Be2 cells depends on both T cells 
and IL-4. Th  is is why B lymphocytes deﬁ  cient  in  the 
receptor for IL-4 do not transcribe IL-4, and why B cells 
primed by IL-4-deﬁ  cient Th  2 cells substitute IFN-γ for 
IL-4. Put simply, Tbet (in T cells, but also in B cells) and 
GATA-3 (in T cells, but also in B cells) suppress cytokines 
synthesized by the opposing Th    cell subpopulation.
B-cell-modulating factors in Sjögren’s syndrome
A new generation of ligands and receptors
Two cytokines and their receptors have been demon-
strated to be key in B-cell homeostasis: BAFF, which 
rescues B cells from apoptosis, and APRIL, which partici-
pates in B-cell activation [63]. Like most members of the 
TNF family, BAFF is a transmembrane type I protein that 
can be cleaved by a furin convertase to produce a 17-kDa 
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trimeric, but 20 trimers can also associate to form a 
virus-like 60-mer structure. APRIL and BAFF, referred to 
as growth factors rather than cytokines by some investi-
gators, have two receptors in common: the B-cell matura-
tion antigen (BCMA) and the transmembrane activator 
calcium modulator and cyclophilin ligand interactor 
(TACI). In addition, BAFF binds speciﬁ   cally to BAFF 
receptor 3 (BR3), whereas heparin sulfate proteoglycans 
are speciﬁ   c receptors for APRIL. BAFF receptors are 
mainly expressed on B cells, but, for each receptor, cell 
membrane density varies from transitional type-1 (T1) 
B lymphocytes to plasma cells. In humans, BR3 is present 
in BT1 cells to memory B cells, but not in plasma cells.
BAFF is critical for B cells to survive in the periphery. It 
is also involved in B-cell selection by dictating set points 
for mature primary B-cell numbers and adjusting 
thresholds for speciﬁ  city-based selection during down-
stream diﬀ  erentiation.  Th  is cytokine has, therefore, 
aroused much interest because of its association with 
maintaining and breaching tolerance (Figure 3). Normally, 
few immature B cells successfully pass to the T2 stage. 
Irrespective of the level of receptor expression, BAFF is 
the dominant agent in the resistance of BT2 cells to 
apoptosis. In its absence, B-cell maturation is arrested at 
the T1 cell stage, while BAFF transgenic mice manifest 
T2 cell hyperplasia in their exocrine glands, which is 
reminiscent of the B-cell aggregates in the SGs of SS 
patients. Th   e mice, then, develop systemic lupus erythe-
matosus and SS-like disease [64]. Th   e explanation is that 
excess BAFF protects self-reactive B cells from deletion 
and allows them to move to forbidden follicle or marginal 
zone (MZ) niches [65].
In the SGs of BAFF transgenic mice, the expanded MZ 
B-cell compartment comprises self-reactive B cells 
[40,64,66], in contrast to a splenic architecture in LTα/β-
deﬁ  cient mice, which lack a structured MZ, preventing 
MZ B-cell development [67]. Noticeable in this regard is 
that the progeny of BAFF transgenic mice crossed with 
LT knockout mice lack MZ B cells and do not develop 
sialadenitis [68]. Th   ese results came as no surprise, while 
more intriguingly, Treg cell expansion through B-cell-
dependent mechanisms [69] leads to profoundly 
compromised T-cell responses [70]. Based on these 
characteristics, BAFF might be regarded as a cytokine 
rather than a growth factor for B cells.
BAFF is produced by all sorts of macrophages and DCs, 
and from epithelial cells and activated T lymphocytes. Its 
mRNA has also been detected in myeloid cells, bone 
marrow-derived stromal cells, astrocytes, and ﬁ  broblast-
like synoviocytes in response to proinﬂ  ammatory cyto-
kines. At the protein level, BAFF exists as a membrane-
associated molecule, or a cell-free protein, whereas 
APRIL occurs only in a soluble form.
BAFF overexpression and Sjögren’s syndrome
Serum levels of BAFF are increased in association with 
auto-antibodies in patients with primary SS. Moreover, 
high levels of BAFF in the serum and saliva of these 
individuals [71] are associated with anti-sicca syndrome 
A and anti-sicca syndrome B antibodies and/or rheuma-
toid factor and/or anti-double-stranded DNA antibody, 
in some [72,73], but not all [74,75], patients with SS, 
rheumatoid arthritis or systemic lupus erythematosus. 
Th  ere exists, however, the issue of why serum levels of 
BAFF remain within, or even below, normal levels in a 
pro  portion of SS patients [76]. In addition, estimates of 
BAFF ﬂ   uctuate with changes in inﬂ  ammatory  activity. 
Convinced that such ﬂ  uctuations could be due to ﬂ  aws or 
variations in enzyme-linked immunosorbent assays, we 
developed an in-house assay [77] and detected elevated 
levels of BAFF in the sera of most SS patients.
BAFF, therefore, is a genuinely promising target for 
therapy, along with IL-6. Such a combination seems to be 
in some conﬂ  ict, since BAFF promotes B-cell responses 
whilst IL-6 promotes the Th   17 axis. However, IL-6 is also 
a prevailing factor in polyclonal activation of B cells, and 
by rescuing B cells from apoptosis, it promotes their 
production of IL-6. It is unclear at this stage which of the 
three cytokines, IL-6, BAFF or IL-17, should be con-
sidered the driving force since IL-6-induced B-cell 
activation also promotes BAFF production [32,38,42,55], 
and since local BAFF gene silencing suppresses Th  17  cell 
generation and ameliorates autoimmune arthritis [78]. 
Th  ese data reveal that IL-17 is an eﬀ  ector cytokine for 
BAFF-mediated proinﬂ  ammatory eﬀ  ects.
Figure 3. In secondary lymphoid organs and salivary glands 
of patients with primary Sjögren’s syndrome, immature B cells 
settle down before further ontogenesis. Transitional type 1 B cells 
(BT1) evolve to BT2 cells, depending on the affi   nity of antigen for 
the B-cell antigen receptor (BCR) and the amount of B-cell activating 
factor (BAFF) of the TNF family. Should the BCR signal be low, they 
move to the marginal zone (MZB); should it be high, they generate 
germinal centers within the follicle (FO).
BT1 BT2
MZB
FO
Higher
BCR
signal
Lower BCR 
signal
BAFF
Pre-B
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provided information on the signaling pathways induced 
by BAFF in the development of SS. Act1 is a negative 
regulator in CD40- and BAFF-mediated B-cell survival 
[79]. It is relevant that co-stimulation with BAFF rescues 
Act1-deﬁ   cient T1 and T2 B lymphocytes from BCR-
induced apoptosis. Consequently, Act1 knockout mice 
develop autoimmune manifestations similar to SS. Th  us, 
Act1 is negative for B-cell-mediated humoral responses 
[80], but instead positive for the IL-17 signaling pathway 
[81].
Th   ere have been reports that the aberrant production 
of these cytokines could be due to excess IFN-α produced 
by plasmacytoid DCs [82]. A credible candidate for the 
induction of IFN-α secretion by plasmacytoid DCs is 
viral infection. Alternatively, IFN-α production in SS may 
be induced by immune complexes containing nucleic 
acids. Th  e role of this cytokine in SS was recently 
reviewed by Mavragani and Crow [83]. Th  ey  highlighted 
the noted increase in circulating type-1 IFN and an IFN 
signature in peripheral blood MNCs and minor SGs from 
SS patients [84]. Altered levels of production of this 
cytokine may be dependent on genetic and/or epigenetic 
mechanisms [85], and its blockade therefore is a logical 
therapeutic target for the treatment of SS.
More importantly, there is good evidence that local 
production of BAFF contributes to deleterious eﬀ  ects of 
activated B cells by raising their expression of CD19 
molecules [4], and ensuring survival of B-cell aggregates, 
and auto-antibody isotype switching outside and inside 
GCs [41]. Th  is process is sustained by the aberrant 
expression of BAFF by B lymphocytes inﬁ  ltrating the SGs 
[86,87].
Aberrant production of BAFF by B cells in SS patients
Indeed, due to the dependency of newly formed B cells 
on BAFF, it is tempting to believe that this cytokine 
needs to be produced in tissue nearby the cell 
aggregates. We have demonstrated aberrant expression 
of BAFF not only in epithelial cells and activated T 
lymphocytes, but also by single cells isolated from the 
SGs and by B lympho  cytes inﬁ   ltrating the SGs of 
patients with SS [87]. Such might be the reason why 
rituximab-induced B-cell depletion reduces the Th  17 
response [88] in rheumatoid arthritis synovium as well 
as that of normal Th   17 cells in the absence of B cells in 
culture. Th  is  ﬁ  nding is also consistent with in vitro and 
in vivo evidence [89] that activation of B cells induces 
BAFF and APRIL expression in B cells from normal and 
autoimmunity-prone mice. Production of BAFF by B 
lymphocytes is unusual, but malignant B cells produce 
BAFF [90], which promotes their survival in an auto-
crine manner. Th   is aberrancy is caused by ampliﬁ  cation 
of the BAFF gene in B cells.
Conclusion
Th   ere is little doubt that exploring the role of cytokines in 
SS is a highly promising ﬁ  eld of investigation. How the 
cells and cytokines interact to promote the development 
of SS is summarized in Figure 4. In general, B-cell deple-
tion has provided clinical beneﬁ  ts [91-95]. Some failures 
might be ascribed [95] to imbalances in Th    cell subsets or 
the depletion of Breg cells. Such striking conceptual 
advances oﬀ   er novel perspectives in the treatment of 
primary SS. Clearly, IL-6, IL-17 and BAFF are major 
agents in the pathogenesis of SS and, therefore, cytokine 
targeting would have great therapeutic potential. 
Nevertheless, B-cell-directed therapies notwithstanding 
[94], much uncertainty remains as to the best therapeutic 
Figure 4. Polarization of T cells and B cells within the salivary 
gland infl  ammatory response. Naïve B cells (B0) polarized in the 
presence of T helper (Th)1 cells are designated B eff  ector (Be)1 
cells. Naïve T cells (Th0) polarized in the presence of Be2 cells are 
designated Th2 cells. Consequently, interconnections exist between 
the B-cell and T-cell cytokine networks. TGF, transforming growth 
factor; T Reg, regulatory T cell.
Th0
IL-2
Th2
Th1
B0
Be2
Be1
Th17
T Reg
IL-7
IL-13
IL-4
IL-6
IFN-γ γ γ γ
IL-2
TNF-α α α α
IL-23
IL-21
IL-1
TGF-β β β β
IL-4
IFN-γ γ γ γ
IL-12
IL-6
Autoimmune Basis of Rheumatic Diseases
This article is part of a series on Sjögren’s syndrome, 
edited by Thomas Dörner, which can be found online at 
http://arthritis-research.com/series/Sjögrens
This series forms part of a special collection of reviews covering major 
autoimmune rheumatic diseases, available at: 
http://arthritis-research.com/series/abrd
Youinou and Pers Arthritis Research & Therapy 2011, 13:227 
http://arthritis-research.com/content/13/4/227
Page 7 of 10strategy for the treatment of SS. Further development of 
biotherapies is beyond the scope of this review. However, 
we can reasonably expect progress in the near future 
based on the aforementioned new insights into distur-
bances of the cytokine networks in SS.
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